B-9-3 concurrently inhibits VEGFA and the PI3K/AKT pathway, potentially enhancing therapeutic efficacy through dual mechanisms of “vascular normalization” and “direct tumor cell killing.” This strategy provides a novel approach to overcoming the drug resistance associated with single-agent anti-angiogenesis therapies (Detmar, 2020; McMahon, 2020). Here, VEGFA is linked to neoplasm.